Literature DB >> 11665985

Membrane complement regulators protect against the development of type II collagen-induced arthritis in rats.

M Mizuno1, K Nishikawa, O B Spiller, B P Morgan, N Okada, H Okada, S Matsuo.   

Abstract

OBJECTIVE: To investigate changes in the distribution patterns of membrane complement regulators (MCRs) during the development of type II collagen-induced arthritis (CIA) and to examine the protective effects of these molecules against the augmentation of CIA in the knee joint.
METHODS: Immunohistochemistry was used to examine the distribution of the MCRs Crry, DAF, and CD59 in the synovium of knee joints before and 2, 4, and 10 weeks after induction of CIA by immunization with type II collagen. In addition, at 2 or 10 weeks after induction of CIA, rats were injected intraarticularly with anti-Crry and/or anti-CD59 as the F(ab')2 fraction of monoclonal antibodies (mAb). Knee joint swelling and histologic changes in the synovium were examined 2 weeks after mAb injection.
RESULTS: Synovial expression of Crry, DAF, and CD59 decreased in parallel with increased inflammation. When Crry and CD59 were functionally blocked at 2 weeks after the induction of CIA, swelling of the knee joints was markedly increased. Blocking of either regulator alone had no effect on swelling. Thickening of the synovial surface and proliferation of subsynovial tissue were all increased after blocking Crry and CD59, whereas blocking of either MCR alone had no effect. When both Crry and CD59 were blocked, deposits of membrane attack complex were found in the synovium.
CONCLUSION: Our findings indicate that in rats with CIA and severely inflamed synovium, local expression of MCR is reduced. The MCRs Crry and CD59 appear to suppress the development of CIA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11665985     DOI: 10.1002/1529-0131(200110)44:10<2425::aid-art407>3.0.co;2-4

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  6 in total

1.  Factor B of the alternative complement pathway regulates development of airway hyperresponsiveness and inflammation.

Authors:  Christian Taube; Joshua M Thurman; Katsuyuki Takeda; Anthony Joetham; Nobuaki Miyahara; Michael C Carroll; Azzeddine Dakhama; Patricia C Giclas; V Michael Holers; Erwin W Gelfand
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-15       Impact factor: 11.205

2.  Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury.

Authors:  Xiufen Zheng; Xusheng Zhang; Biao Feng; Hongtao Sun; Motohiko Suzuki; Thomas Ichim; Norihiko Kubo; Arthur Wong; Lisa R Min; Marianne E Budohn; Bertha Garcia; Anthony M Jevnikar; Wei-Ping Min
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

3.  A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration.

Authors:  Siobhan M Cashman; Kasmir Ramo; Rajendra Kumar-Singh
Journal:  PLoS One       Date:  2011-04-28       Impact factor: 3.240

4.  Soluble CD59 expressed from an adenovirus in vivo is a potent inhibitor of complement deposition on murine liver vascular endothelium.

Authors:  Jarel Gandhi; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

5.  Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis.

Authors:  Anne R Kinderlerer; Rivka Steinberg; Michael Johns; Sarah K Harten; Elaine A Lidington; Dorian O Haskard; Patrick H Maxwell; Justin C Mason
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

Review 6.  Complement in the Initiation and Evolution of Rheumatoid Arthritis.

Authors:  V Michael Holers; Nirmal K Banda
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.